Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 186
Filter
4.
Parkinsonism Relat Disord ; : 106974, 2024 Apr 23.
Article in English | MEDLINE | ID: mdl-38670906

ABSTRACT

This article explores the potential link between COVID-19 and parkinsonism, synthesizing existing evidence and recent research findings. It highlights limitations in current understanding, emphasizes the direct impact of the virus on dopamine neurons, and calls for continued research to elucidate long-term neurological implications and optimize patient care strategies.

5.
Expert Rev Neurother ; 24(5): 527-539, 2024 May.
Article in English | MEDLINE | ID: mdl-38597219

ABSTRACT

INTRODUCTION: This systematic review and meta-analysis evaluates the evidence from randomized controlled trials (RCTs) involving pharmacological interventions for improving sleep in people with Alzheimer's disease (AD). METHODS: A systematic literature search in eight databases from January 2000 to July 2023 focusing on RCTs that compared a pharmacological intervention with a placebo for enhancing sleep in people with AD. The authors registered the study protocol at Prospero, followed the PRISMA guidelines, and produced the pooled estimates using random-effect or IVhet models. RESULTS: Eight different interventions and 29 different sleep outcomes were examined in 14 RCTs included in this review. Eszopiclone positively affected sleep efficiency, as did orexin antagonists. However, there was no difference when melatonin was used. The interventions demonstrated low discontinuation rates and a few adverse drug reactions. CONCLUSION: Although melatonin was the most investigated intervention, the evidence for its efficacy is inconclusive. On the other hand, trazodone and orexin receptor antagonists showed promising results; however, more RCTs are needed for definite answers.


Subject(s)
Alzheimer Disease , Melatonin , Trazodone , Humans , Alzheimer Disease/complications , Alzheimer Disease/drug therapy , Melatonin/therapeutic use , Melatonin/pharmacology , Randomized Controlled Trials as Topic , Sleep , Trazodone/adverse effects
7.
Int J Pharm Pract ; 32(3): 259-264, 2024 May 07.
Article in English | MEDLINE | ID: mdl-38438314

ABSTRACT

OBJECTIVES: To determine risks associated with uricosurics in COVID-19 patients. METHODS: A systematic review and meta-analysis was conducted by systematically searching electronic databases. KEY FINDINGS: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94). CONCLUSIONS: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.


Subject(s)
Ascorbic Acid , COVID-19 , Randomized Controlled Trials as Topic , Uric Acid , Humans , COVID-19/mortality , Uric Acid/blood , Ascorbic Acid/therapeutic use , COVID-19 Drug Treatment , Antioxidants/therapeutic use
8.
Expert Rev Endocrinol Metab ; 19(2): 141-154, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38347803

ABSTRACT

INTRODUCTION: Type 2 diabetes (T2D) presents significant global health and economic challenges, contributing to complications such as stroke, cardiovascular disease, kidney dysfunction, and cancer. The current review explores the crucial role of mitochondria, essential for fuel metabolism, in diabetes-related processes. AREAS COVERED: Mitochondrial deficits impact insulin-resistant skeletal muscles, adipose tissue, liver, and pancreatic ß-cells, affecting glucose and lipid balance. Exercise emerges as a key factor in enhancing mitochondrial function, thereby reducing insulin resistance. Additionally, the therapeutic potential of mitochondrial uncoupling, which generates heat instead of ATP, is discussed. We explore the intricate link between mitochondrial function and diabetes, investigating genetic interventions to mitigate diabetes-related complications. We also cover the impact of insulin deficiency on mitochondrial function, the role of exercise in addressing mitochondrial defects in insulin resistance, and the potential of mitochondrial uncoupling. Furthermore, a comprehensive analysis of Mitochondrial Replacement Therapies (MRT) techniques is presented. EXPERT OPINION: MRTs hold promise in preventing the transmission of mitochondrial disease. However, addressing ethical, regulatory, and technical considerations is crucial. Integrating mitochondrial-based treatments requires a careful balance between innovation and safety. Ethical dimensions and regulatory aspects of MRT are examined, emphasizing collaborative efforts for the responsible advancement of human health.


Subject(s)
Diabetes Mellitus, Type 2 , Insulin Resistance , Humans , Diabetes Mellitus, Type 2/genetics , Insulin Resistance/physiology , Mitochondria/genetics , Mitochondria/metabolism , Insulin , Glucose/metabolism
13.
Int J Pharm Pract ; 32(1): 100-103, 2024 Feb 15.
Article in English | MEDLINE | ID: mdl-38029419

ABSTRACT

OBJECTIVE: The aim of this study was to examine the impact of pharmacy automation on the workload and satisfaction of pharmacists and pharmacy assistants in an inpatient setting. METHODS: This was an observational, cross-sectional survey using a convenience sampling method conducted at the University Malaya Medical Centre (UMMC) In-Patient Pharmacy. A validated online questionnaire assessed user satisfaction and task duration. RESULTS: A total of 21 pharmacists and 18 pharmacy assistants participated in the survey. Most pharmacists (n = 17/21) were confident in the system, and both pharmacists and pharmacy assistants perceived it to be beneficial for patients (n = 33/39) and for reducing medication errors (n = 32/39). Pharmacy assistants spent approximately 5.34 hours on traditional work including filling medication orders (1.44 hours) after automated tablet dispensing and packaging system (ATDPS) implementation. Pharmacists spent 1.19 hours filling medication orders and 1.71 hours checking/verifying them, in contrast. CONCLUSION: Pharmacists focused mainly on clinical duties with healthcare colleagues, while pharmacy assistants handled various medication orders. Nevertheless, ATDPS reduced pharmacy staff workload in medication handling, achieving user satisfaction.


Subject(s)
Pharmacy Service, Hospital , Pharmacy , Humans , Cross-Sectional Studies , Hospitals, University , Malaysia , Personal Satisfaction , Pharmacists , Workload
16.
Health Sci Rep ; 6(11): e1642, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37915365

ABSTRACT

Background and Aims: Diabetes is a global concern. This article took a closer look at diabetes and precision medicine. Methods: A literature search of studies related to the use of precision medicine in diabetes care was conducted in various databases (PubMed, Google Scholar, and Scopus). Results: Precision medicine encompasses the integration of a wide array of personal data, including clinical, lifestyle, genetic, and various biomarker information. Its goal is to facilitate tailored treatment approaches using contemporary diagnostic and therapeutic techniques that specifically target patients based on their genetic makeup, molecular markers, phenotypic traits, or psychosocial characteristics. This article not only highlights significant advancements but also addresses key challenges, particularly focusing on the technologies that contribute to the realization of personalized and precise diabetes care. Conclusion: For the successful implementation of precision diabetes medicine, collaboration and coordination among multiple stakeholders are crucial.

19.
Inflammopharmacology ; 31(6): 3339-3355, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37804462

ABSTRACT

BACKGROUND: The use of anti-CD20 monoclonal antibodies, such as rituximab and ocrelizumab, has emerged as a matter of concern, in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: We aimed to summarize the overall evidence on the pre-admission/pre-diagnosis use of anti-CD20 among patients with COVID-19 with regards to mortality and severe illness outcomes. METHODS: A systematic literature search with no language restriction was performed in electronic databases, including PubMed, Google Scholar, Scopus, and preprint servers (medRxiv, Research Square, SSRN), to identify eligible studies published up to June 13, 2023. The outcomes of interest were the development of severe illness and all-cause mortality. A random-effects model was used to estimate the pooled odds ratio for outcomes of interest using anti-CD20 monoclonal antibodies relative to non-use of anti-CD20 monoclonal antibodies, at 95% confidence intervals. RESULTS: Our systematic review and meta-analysis revealed significantly increased odds for development of severe illness (pooled odds ratio 2.95; 95% confidence interval 2.30, 3.78; n = 534,349) and significantly increased odds for mortality (pooled odds ratio 2.14; 95% confidence interval 1.37, 3.35; n = 333,462) with the use of anti-CD20 monoclonal antibodies, relative to non-use of anti-CD20 monoclonal antibodies, in patients with COVID-19. CONCLUSION: Healthcare practitioners should exercise caution when prescribing these anti-CD20 monoclonal antibodies during the COVID-19 pandemic to patients who are indicated for these agents, particularly those with underlying conditions like multiple sclerosis or rheumatoid arthritis.


Subject(s)
Antineoplastic Agents , COVID-19 , Multiple Sclerosis , Humans , Pandemics , Antibodies, Monoclonal/adverse effects
20.
Inflammopharmacology ; 31(6): 3327-3332, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37848697

ABSTRACT

Probiotics have been hypothesized to play a beneficial role in modulating immune responses and gut microbiota in various clinical settings. This systematic review and meta-analysis aimed to assess the effectiveness of probiotics in reducing all-cause mortality among patients diagnosed with COVID-19. We conducted a comprehensive search of the following databases: PubMed, Scopus, and Web of Science for published studies, and medRxiv, Research Square, and SSRN for preprints. The search spanned from the inception of these databases to April 4, 2023. We included studies that investigated the use of probiotics as an intervention and their impact on all-cause mortality in patients with COVID-19. A random-effects model meta-analysis was employed to estimate the pooled odds ratio, along with 95% confidence interval, to quantify the outcomes associated with probiotic use compared to other interventions. Our systematic review comprised six studies, encompassing a total of 642 patients. The meta-analysis, employing a random-effects model, demonstrated a statistically significant reduction in the risk of all-cause mortality when probiotics were administered to patients with COVID-19, compared to those not receiving probiotics (pooled odds ratio = 0.44; 95% confidence interval 0.24-0.82). In conclusion, evidence derived from randomized controlled trials (RCTs) indicates a survival benefit associated with the use of probiotics among COVID-19 patients. However, it is essential to exercise caution and await data from large-scale randomized trials to definitively confirm the mortality benefits of probiotics in this patient population.


Subject(s)
COVID-19 , Gastrointestinal Microbiome , Probiotics , Humans , COVID-19/therapy , Randomized Controlled Trials as Topic , Probiotics/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...